Last reviewed · How we verify
YL-13027
At a glance
| Generic name | YL-13027 |
|---|---|
| Also known as | YL-13027 tablet |
| Sponsor | Shanghai YingLi Pharmaceutical Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer (PHASE1)
- YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer (PHASE1, PHASE2)
- A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- YL-13027 in Patients With Advanced Solid Tumors (PHASE1)
- First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YL-13027 CI brief — competitive landscape report
- YL-13027 updates RSS · CI watch RSS
- Shanghai YingLi Pharmaceutical Co. Ltd. portfolio CI